ClinicalTrials.gg
RecruitingNCT06493760Updated Sep 19, 2024

A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients

A Phase 2 interventional study of SSGJ-707 and Bevacizumab in Metastatic Colorectal Cancer, sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (part of 3SBio Inc.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
130
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies testing oxaliplatin in Colorectal Neoplasms — 21 open to participants now, 25 under way, 6 of them phase 3. Oxaliplatin · Colorectal Neoplasms.

Planned enrollment
50th of 183
130 · median 50
Started
2024
with 4 others
Phase 2
110 of 206
12 open now
Primary completion
2025-06
later than 4 of 24 live
Registered
198th of 206
by date

Among the 206 studies testing oxaliplatin in Colorectal Neoplasms, this one is the 50th largest by planned enrollment of the 183 interventional ones that give a count, is one of 5 that started in 2024, is one of 110 in phase 2, reaches primary completion later than 4 of the 24 other live ones, and was the 198th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

21 of the 206 studies testing oxaliplatin in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About oxaliplatin

Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies testing oxaliplatin in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This study includes two parts:Part 1: SSGJ-707 (different dosing regimens) in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.Part 2: SSGJ-707 in combination with chemotherapy versus bevacizumab in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • SSGJ-707
  • colorectal cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and/or females over age 18
  2. and/or cytologically documented colorectal cancer confirmed .
  3. (ECOG) performance status of 0-1.
  4. Expected survival >=12 weeks.
  5. Signed form.

Exclusion criteria

Exclusion Criteria:

  1. Known uncontrolled or symptomatic central nervous system disease.
  2. Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade >1 (National Cancer Institute Common terminology Criteria [] v.5.0).
  3. Inadequate organ or bone marrow function.
  4. Pregnant or breast-feeding woman.
  5. Known allergies, , or intolerance to SSGJ-707 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    SSGJ-707(dose 1)+ XELOX

    Drug: SSGJ-707 · Drug: Oxaliplatin · Drug: Capecitabine

  • Experimental
    SSGJ-707(dose 1)+ mFOLFOX6

    Drug: SSGJ-707 · Drug: Oxaliplatin · Drug: Calcium Folinate · Drug: 5-fluorouracil

  • Experimental
    SSGJ-707(dose 2)+ XELOX

    Drug: SSGJ-707 · Drug: Oxaliplatin · Drug: Capecitabine

  • Experimental
    SSGJ-707(dose 2)+ mFOLFOX6

    Drug: SSGJ-707 · Drug: Oxaliplatin · Drug: Calcium Folinate · Drug: 5-fluorouracil

  • Experimental
    SSGJ-707+XELOX/mFOLFOX6

    Drug: SSGJ-707 · Drug: Oxaliplatin · Drug: Capecitabine · Drug: Calcium Folinate · Drug: 5-fluorouracil

  • Active comparator
    Bevacizumab+XELOX/mFOLFOX6

    Drug: Bevacizumab · Drug: Oxaliplatin · Drug: Capecitabine · Drug: Calcium Folinate · Drug: 5-fluorouracil

  • Experimental
    SSGJ-707 monotherapy

    Drug: SSGJ-707

Interventions

06

What researchers measure

Primary outcomes

  1. ORR

    Objective response rate

    Time frame: 12 months

  2. Safety and tolerability

    Safety and tolerability assessed by incidence and severity of adverse events

    Time frame: 12 months

Secondary outcomes

  1. PFS

    The efficacy end points

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
  • Liu Tianshu
    Shanghai, Shanghai, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Jun 2025, 9 months after the start.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's planned 9 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2024
First posted
Jul 10, 2024
StartActual
Sep 3, 2024
Primary completionEst.
Jun 2025
CompletionEst.
Jun 2027
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06493760
Responsible party
Sponsor
First posted
Jul 10, 2024
Start date
Sep 3, 2024
Primary completion
Jun 2025 (estimated)
Completion
Jun 2027 (estimated)
Last update
Sep 19, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404 · Oxaliplatin · Capecitabine · Leucovorin · Fluorouracil

Start the discussion